JP6546654B2 - 淋菌感染を治療するための三環式含窒素化合物 - Google Patents

淋菌感染を治療するための三環式含窒素化合物 Download PDF

Info

Publication number
JP6546654B2
JP6546654B2 JP2017510528A JP2017510528A JP6546654B2 JP 6546654 B2 JP6546654 B2 JP 6546654B2 JP 2017510528 A JP2017510528 A JP 2017510528A JP 2017510528 A JP2017510528 A JP 2017510528A JP 6546654 B2 JP6546654 B2 JP 6546654B2
Authority
JP
Japan
Prior art keywords
dihydro
mmol
methyl
piperidinyl
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017510528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524029A5 (https=
JP2017524029A (ja
Inventor
キャサリン、ルイザ、ウィドウソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2017524029A publication Critical patent/JP2017524029A/ja
Publication of JP2017524029A5 publication Critical patent/JP2017524029A5/ja
Application granted granted Critical
Publication of JP6546654B2 publication Critical patent/JP6546654B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017510528A 2014-08-22 2015-08-20 淋菌感染を治療するための三環式含窒素化合物 Active JP6546654B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040488P 2014-08-22 2014-08-22
US62/040,488 2014-08-22
PCT/IB2015/056325 WO2016027249A1 (en) 2014-08-22 2015-08-20 Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019115462A Division JP2019189629A (ja) 2014-08-22 2019-06-21 淋菌感染を治療するための三環式含窒素化合物

Publications (3)

Publication Number Publication Date
JP2017524029A JP2017524029A (ja) 2017-08-24
JP2017524029A5 JP2017524029A5 (https=) 2019-01-31
JP6546654B2 true JP6546654B2 (ja) 2019-07-17

Family

ID=54072911

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017510528A Active JP6546654B2 (ja) 2014-08-22 2015-08-20 淋菌感染を治療するための三環式含窒素化合物
JP2019115462A Withdrawn JP2019189629A (ja) 2014-08-22 2019-06-21 淋菌感染を治療するための三環式含窒素化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019115462A Withdrawn JP2019189629A (ja) 2014-08-22 2019-06-21 淋菌感染を治療するための三環式含窒素化合物

Country Status (22)

Country Link
US (2) US10702521B2 (https=)
EP (2) EP3182973B1 (https=)
JP (2) JP6546654B2 (https=)
KR (1) KR20170043603A (https=)
CN (2) CN110403939A (https=)
AR (1) AR101674A1 (https=)
AU (1) AU2015304847B2 (https=)
BR (1) BR112017003705B1 (https=)
CA (1) CA2958800C (https=)
CL (1) CL2017000391A1 (https=)
CO (1) CO2017001658A2 (https=)
CR (1) CR20170069A (https=)
DO (1) DOP2017000049A (https=)
EA (1) EA031589B1 (https=)
ES (1) ES2759303T3 (https=)
IL (1) IL250251A0 (https=)
MX (1) MX2017002321A (https=)
PE (1) PE20170501A1 (https=)
PH (1) PH12017500315A1 (https=)
SG (1) SG11201700566SA (https=)
TW (1) TW201618779A (https=)
WO (1) WO2016027249A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019189629A (ja) * 2014-08-22 2019-10-31 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 淋菌感染を治療するための三環式含窒素化合物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018075297A2 (pt) * 2016-06-08 2019-03-19 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A composto, composição farmacêutica, e, método para tratar uma infecção bacteriana
CA3045224A1 (en) 2016-12-16 2018-06-21 Basf Se Pesticidal compounds
WO2020201833A1 (en) * 2019-04-03 2020-10-08 Glaxomithkline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial urinary tract infections
US20220184071A1 (en) * 2019-04-03 2022-06-16 Glaxosmithkline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial urinary tract infections
GB201909191D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
CN114173789A (zh) * 2019-07-05 2022-03-11 葛兰素史克知识产权发展有限公司 用于治疗由生殖支原体引起的感染的组合
IL293340A (en) 2019-12-02 2022-07-01 Storm Therapeutics Ltd Polyheterocyclic compounds as mettl3 inhibitors
ES3004932T3 (en) 2020-04-02 2025-03-13 Glaxosmithkline Ip Dev Ltd Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
WO2021219671A1 (en) * 2020-04-28 2021-11-04 Noorik Biopharmaceuticals Ag Treatment of pulmonary complications of coronavirus infections
EP4143188A1 (en) * 2020-04-29 2023-03-08 GlaxoSmithKline Intellectual Property Development Limited Crystalline forms of gepotidacin
CA3210313A1 (en) * 2021-02-05 2022-08-11 Glaxosmithkline Intellectual Property Development Limited Oral solid dose formulations
EP4316463A1 (en) 2022-08-02 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Novel formulation
CN119546302A (zh) 2022-09-26 2025-02-28 葛兰素史密斯克莱知识产权发展有限公司 用于治疗细菌性前列腺炎的吉泊达星
CN121537412B (zh) * 2026-01-16 2026-04-03 南京道尔医药研究院有限公司 一种吉泊达星甲磺酸盐的制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA931343B (en) 1992-03-06 1993-09-24 Akzo Nv 1,4-dioxino(2,3-b)pyridine derivatives.
DK0624376T3 (da) * 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
GB0207450D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
DE60025048D1 (de) 2000-07-21 2006-01-26 Ljudmila Petrovna Maljuk Teller für stehempfänge
CZ2003243A3 (cs) 2000-07-26 2003-09-17 Smithkline Beecham P. L. C. Aminopiperidinové chinoliny a jejich azaisosterické analogy s antibakteriální aktivitou
IL155092A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
EP1345903A1 (en) 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
EP1470125A1 (en) 2002-01-29 2004-10-27 Glaxo Group Limited Aminopiperidine derivatives
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
WO2004035569A2 (de) 2002-10-10 2004-04-29 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue verbindungen mit antibakterieller aktivität
ATE479683T1 (de) 2002-11-05 2010-09-15 Glaxo Group Ltd Antibakterielle mittel
DE60331849D1 (de) 2002-11-05 2010-05-06 Glaxosmithkline Llc Antibakterielle wirkstoffe
TW200427688A (en) 2002-12-18 2004-12-16 Glaxo Group Ltd Antibacterial agents
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
WO2004104000A1 (ja) 2003-05-23 2004-12-02 Japan Tobacco Inc. トリサイクリック縮合環化合物およびその医薬用途
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US7691850B2 (en) 2004-06-15 2010-04-06 Glaxo Group Limited Antibacterial agents
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US20070254872A1 (en) 2004-07-08 2007-11-01 Glaxo Group Limited Antibacterial Agents
US20080194547A1 (en) 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
US7648984B2 (en) 2004-07-13 2010-01-19 Glaxo Group Limited Antibacterial agents
US20070270417A1 (en) 2004-07-22 2007-11-22 Glaxo Group Limited Antibacterial Agents
US7655648B2 (en) 2004-08-02 2010-02-02 Glaxo Group Limited Antibacterial agents
US20070161627A1 (en) 2004-08-09 2007-07-12 Miller William H Antibacterial agents
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
CA2580621A1 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
WO2006038172A1 (en) 2004-10-05 2006-04-13 Actelion Pharmaceuticals Ltd New piperidine antibiotics
JP5314244B2 (ja) 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
US7709472B2 (en) 2005-01-25 2010-05-04 Glaxo Group Limited Antibacterial agents
JP2008528604A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
EP1846418A4 (en) 2005-01-25 2009-12-23 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
JP2008528598A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
US7648980B2 (en) 2005-01-25 2010-01-19 Glaxo Group Limited Antibacterial agents
WO2006099884A1 (en) 2005-03-24 2006-09-28 Actelion Percurex Ag Beta-aminoalcohol antibiotics
NZ562034A (en) 2005-03-31 2009-10-30 Janssen Pharmaceutica Nv Bicyclic pyrazole compounds as antibacterial agents
TW200716132A (en) 2005-05-03 2007-05-01 Smithkline Beecham Corp Novel chemical compounds
EP1891078A1 (en) 2005-05-24 2008-02-27 AstraZeneca AB Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
WO2006126171A2 (en) 2005-05-25 2006-11-30 Actelion Pharmaceuticals Ltd New antibiotic derivatives
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2006137485A1 (ja) 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
WO2007016610A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited Antibacterial agents
KR20080064173A (ko) 2005-10-21 2008-07-08 글락소 그룹 리미티드 항균제로서 유용한 페리 축합 트리시클릭 화합물
WO2007067511A2 (en) 2005-12-06 2007-06-14 Merck & Co., Inc. Morpholine carboxamide prokineticin receptor antagonists
ATE465163T1 (de) 2005-12-22 2010-05-15 Glaxo Group Ltd Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
EP2007377A4 (en) 2006-04-06 2011-08-17 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
WO2007115947A1 (en) 2006-04-06 2007-10-18 Glaxo Group Limited Pyrrolo-quinoxalinone derivatives as antibacterials
GB0608263D0 (en) 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
US20100256124A1 (en) 2006-06-09 2010-10-07 David Thomas Davies Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
EA015821B1 (ru) * 2007-04-20 2011-12-30 Глэксо Груп Лимитед Трициклические азотсодержащие соединения в качестве антибактериальных агентов
BRPI0912995A2 (pt) * 2008-05-23 2015-10-13 Glaxo Group Ltd compostos tricíclicos contendo nitrogênio e sua utilização como agentes antibacterianos
WO2010043714A1 (en) * 2008-10-17 2010-04-22 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials
JP6546654B2 (ja) * 2014-08-22 2019-07-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 淋菌感染を治療するための三環式含窒素化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019189629A (ja) * 2014-08-22 2019-10-31 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 淋菌感染を治療するための三環式含窒素化合物

Also Published As

Publication number Publication date
US11229646B2 (en) 2022-01-25
US20200330462A1 (en) 2020-10-22
CN106659717B (zh) 2019-09-06
PH12017500315A1 (en) 2017-07-10
CA2958800A1 (en) 2016-02-25
CO2017001658A2 (es) 2017-07-19
CR20170069A (es) 2017-04-28
ES2759303T3 (es) 2020-05-08
CA2958800C (en) 2020-10-27
MX2017002321A (es) 2017-08-02
CN106659717A (zh) 2017-05-10
IL250251A0 (en) 2017-03-30
SG11201700566SA (en) 2017-03-30
EA201790442A1 (ru) 2017-08-31
BR112017003705A2 (pt) 2017-12-05
EA031589B1 (ru) 2019-01-31
CL2017000391A1 (es) 2017-08-18
US10702521B2 (en) 2020-07-07
WO2016027249A1 (en) 2016-02-25
EP3182973A1 (en) 2017-06-28
JP2017524029A (ja) 2017-08-24
AU2015304847B2 (en) 2018-10-25
TW201618779A (zh) 2016-06-01
CN110403939A (zh) 2019-11-05
BR112017003705B1 (pt) 2022-07-12
JP2019189629A (ja) 2019-10-31
AU2015304847A1 (en) 2017-02-23
AR101674A1 (es) 2017-01-04
EP3639824A1 (en) 2020-04-22
PE20170501A1 (es) 2017-04-27
EP3182973B1 (en) 2019-09-18
DOP2017000049A (es) 2017-03-15
US20170304301A1 (en) 2017-10-26
KR20170043603A (ko) 2017-04-21

Similar Documents

Publication Publication Date Title
US11229646B2 (en) Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione
JP5389013B2 (ja) 抗菌剤としての三環式含窒素化合物
JP2009532423A (ja) 抗菌剤としてのピロロ−キノキサリノン誘導体
JP2010521518A (ja) 化合物
US20100184751A1 (en) Heterocyclic compounds for the treatment of tuberculosis
US20110009394A1 (en) Tricyclic nitrogen compounds and their use as antibacterial agents
US20110275661A1 (en) Tricyclic nitrogen compounds used as antibacterials
JP2010524890A (ja) 化合物
ES2351377T3 (es) Compuestos tricíclicos que contienen nitrógeno como agentes antibacterianos.
HK1138000B (en) Tricyclic nitrogen containing compounds as antibacterial agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180614

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180614

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20180626

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180626

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181130

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20181214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190621

R150 Certificate of patent or registration of utility model

Ref document number: 6546654

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250